Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo

BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more

By Paul Bonanos, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst
November 19, 2024 1:28 AM UTC

Two Western biopharmas made headlines last week by entering deals with China-based biotechs around an emerging class of bispecifics, and the drumbeat continued early this week with more deals for other bifunctional antibodies.

The bigger deals drawing attention were around anti-PD-(L)1 x VEGF bispecifics, as BioNTech SE (NASDAQ:BNTX) acquired Biotheus Inc. for $800 million up front, and Merck & Co. Inc. (NYSE:MRK) took global rights to a program from LaNova Medicines Ltd. for $588 million...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

3b Pharmaceuticals GmbH

Aclaris Therapeutics Inc.

Artbio Inc.

Atsena Therapeutics Inc.

Avenzo Therapeutics Inc.

Biontech SE

Biosion Inc.